-
CDK9 inhibitor A3294: Practical Protocol Guide
2026-09-04
CDK9 inhibitor A3294 provides a selective tool for examining CDK9-dependent transcription elongation and P-TEFb-related HIV-1 propagation workflows while limiting interpretation from broad CDK inhibition. It is suited to controlled biochemical and cell-based studies, but not to pan-CDK experiments, general conclusions about cell cycle regulation, or long-term storage of prepared solutions.
-
Polybrene (Hexadimethrine Bromide): Use & Limits
2026-09-04
Polybrene, also called Hexadimethrine Bromide, is a cationic polymer used to improve viral gene delivery and selected transfection workflows. The 10 mg/mL formulation supports reproducible handling, but cell-specific toxicity testing and assay controls remain essential.
-
CCR7–Notch1 Crosstalk Drives Mammary Cancer Stemness
2026-09-03
Boyle et al. identify functional crosstalk between CCR7 and Notch1 in primary MMTV-PyMT mammary cancer cells, linking chemokine signaling to maintenance of a stem-like tumor-cell state. Their combination of CCR7 loss-of-function, pathway inhibition, molecular readouts, and cellular assays supports dual-axis investigation while also highlighting the limits of extrapolating cell-based findings to therapeutic efficacy.
-
Eldecalcitol, Endothelial Ferroptosis, and T2DOP
2026-09-03
A 2025 study identifies endothelial ferroptosis as a mechanistic contributor to type 2 diabetic osteoporosis and proposes an SOCE/O-GlcNAcylation pathway through which eldecalcitol may restore vascular–bone coupling. Its combined cell and mouse experiments connect redox injury, type H vessel dysfunction, and impaired osteogenesis, while highlighting pharmacological pathway validation as an important next step.
-
Sulforaphane Suppresses NLRP3 in Ulcerative Colitis
2026-09-02
The reference study integrates a dextran sodium sulfate mouse model with RAW264.7 cell experiments to show that Sulforaphane reduces oxidative stress and suppresses NLRP3 inflammasome activation during colitis. Its main practical contribution is a mechanistic link between reactive oxygen species and inflammatory signaling, while its findings remain preclinical and model-dependent.
-
Cell Counting Kit-8 Plus for Ferroptosis Studies
2026-09-02
Cell Counting Kit-8 Plus provides a fast, water-soluble WST-8 readout for connecting colorectal cancer cell survival with SLC11A1-associated ferroptosis resistance. This workflow emphasizes assay design, metabolic confounder controls, and orthogonal validation rather than treating absorbance as a direct cell count.
-
Deracoxib and Piroxicam in Canine Osteosarcoma
2026-09-01
This 2005 study compared deracoxib and piroxicam across canine osteosarcoma cell lines and found that deracoxib produced more consistent, concentration-dependent loss of viability. Its selective effect relative to fibroblasts supports further investigation, while the absence of DNA fragmentation cautions against assuming that apoptosis explains the observed cytotoxicity.
-
Topotecan HCl Workflows for DNA Damage Studies
2026-09-01
Topotecan HCl provides a controllable topoisomerase 1 inhibitor workflow for linking replication-associated DNA damage with cell death, while supporting lung, prostate, breast, and exploratory neuroinflammation assays. This guide combines product-backed exposure ranges with practical controls, endpoint selection, and safeguards against confusing general toxicity with pathway-specific effects.
-
11β-HSD1 Inhibition in Liver Fibrosis
2026-08-31
A 2025 mouse study shows that a novel 11β-HSD1 inhibitor reduces thioacetamide-associated liver fibrosis through coordinated suppression of Notch signaling and enhancement of natural killer cell responses. The work links local cortisol regulation with hepatic stellate-cell activation and immune-mediated clearance, providing a mechanistic framework for evaluating new antifibrotic strategies while underscoring the limits of translation from a toxin-induced model.
-
Risedronate Sodium: Workflows for Bone Research
2026-08-31
Risedronate Sodium gives researchers a practical route to study FPPS-dependent osteoclast biology, bone resorption, and formulation-enhanced delivery. This guide translates published nanotransfersome–microneedle data into bench workflows, assay choices, and troubleshooting strategies for skeletal and exploratory pulmonary research.
-
Adefovir (GS-0393) Research Workflows
2026-08-30
Adefovir (GS-0393) supports two complementary research applications: mechanistic HBV polymerase studies and quantitative OAT1 transport profiling. This guide converts those properties into practical assay workflows, exposure-aware comparisons, and troubleshooting strategies for reproducible hepatitis B virus research.
-
FBXO22 Recruitment Ligands Expand Protein Degradation
2026-08-29
This 2025 bioRxiv preprint introduces chemical probes that define two complementary ways to engage the cancer-associated E3 ligase FBXO22: selective self-degradation and recruitment of the ligase to new protein targets. The identification of 2-pyridinecarboxaldehyde as a reversible cysteine-reactive degron expands the ligand space available for targeted protein degradation while providing practical probes for studying FBXO22 biology.
-
Heparin Sodium at the Nanovesicle–Coagulation Interface
2026-08-28
Heparin sodium is more than a standard anticoagulant: it can anchor reproducible coagulation assays while providing a carefully bounded probe of heparan sulfate proteoglycan-dependent nanovesicle uptake. This article connects the reference study on Cistanche deserticola nanovesicles and Sertoli-cell recovery with practical translational workflows, emphasizing assay controls, mechanistic limits, and research-only interpretation.
-
GM 6001 (Galardin): Assay Reliability Guide
2026-08-28
A practical, scenario-based guide to using GM 6001 (Galardin), SKU A4050, when MMP activity complicates viability, proliferation, migration, or extracellular matrix assays. It covers mechanism, DMSO stock preparation, controls, interpretation, and vendor-selection criteria supported by product data and cited research.
-
Intestinal TM6SF2 Protects Against MASH
2026-08-27
A 2025 Nature Metabolism study shows that intestinal epithelial TM6SF2 protects against MASH by maintaining barrier integrity and limiting lipid-driven microbiota and lysophosphatidic acid signaling. Conditional knockout, fecal-transfer, co-housing, and pharmacological experiments establish a causal gut–liver pathway and identify LPA receptor blockade as a testable intervention.